Stimuli-responsive nanoscale drug delivery system for epilepsy theranostics
Source abstract
Abstract
Epilepsy is a common neurological disease characterized by distinct pathological changes in the epileptogenic zone. Antiseizure drugs (ASDs) are widely used as the primary treatment for epilepsy. To improve the efficiency of ASDs medication, stimuli-responsive nanoscale drug delivery systems (nanoDDSs), triggered by either endogenous or exogenous factors, have been developed and been considered as a noninvasive and spatial-temporal approach to epilepsy theranostics. In this review, we introduce the pathological variations observed in epileptic lesions such as dysregulated neurotransmitter systems, disrupted ion homeostasis, and dynamic inflammatory cytokine networks. Furthermore, we summarize the recent advances in functional nano-assemblies that could be activated by endogenous stimuli of pathological alterations or exogenous stimuli such as electricity, light, and other interventions. Finally, we discuss the remaining challenges and prospect the insight into perspective of future development in this field. In summary, this review aims to highlight the potential of stimuli-responsive nanoDDSs as precise, controllable and efficient strategies for addressing unresolved issues in epilepsy theranostics. STATEMENT OF SIGNIFICANCE: This review summarizes recent progress in pathological changes such as dysregulated neurotransmitter system, disrupted ion homeostasis and dynamic inflammatory cytokine network, and emphasizes endogenous/exogenous stimuli-responsive nanoscale platforms including neurotransmitter-, ion-, and other stimuli-responsive nanoDDSs, providing the prospects of smart nanoDDSs applications and discussing the challenges to offer generalized guideline for further development of epilepsy theranostics.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Lipid Membrane Structure and Behavior · Neuroscience and Neural Engineering
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE)10.1111/j.0013-9580.2005.66104.x ↗
2. Epilepsy and cognition10.1016/j.yebeh.2003.07.004 ↗
3. The neurobiology of epilepsy10.1007/s11910-007-0053-z ↗
4. Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options10.1124/pr.120.019539 ↗
5. Epilepsy in adults10.1016/S0140-6736(18)32596-0 ↗
6. The epidemiology of global epilepsy10.1016/j.ncl.2016.06.015 ↗
7. Effects of chronic epilepsy on intellectual functions10.1016/S0079-6123(02)35042-8 ↗
8. Ictal hypoxemia in localization-related epilepsy: analysis of incidence, severity and risk factors10.1093/brain/awn277 ↗
9. Antiseizure medications and sudden unexpected death in epilepsy: an updated review10.1007/s40263-024-01112-0 ↗
10. Current state of the epilepsy drug and device pipeline10.1111/epi.17884 ↗
11. Antiseizure medications for adults with epilepsy: a review10.1001/jama.2022.3880 ↗
12. Innovative drug discovery strategies in epilepsy: integrating next-generation syndrome-specific mouse models to address pharmacoresistance and epileptogenesis10.1080/17460441.2024.2384455 ↗
13. Shortcomings in the current treatment of epilepsy10.1586/ern.12.129 ↗
14. In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats10.1046/j.1528-1157.2001.01901.x ↗
15. Wearable digital health technology for epilepsy10.1056/NEJMra2301913 ↗
16. Drug resistance in epilepsy10.1016/S1474-4422(23)00151-5 ↗
17. Pluronic P85-coated poly(butylcyanoacrylate) nanoparticles overcome phenytoin resistance in P-glycoprotein overexpressing rats with lithium-pilocarpine-induced chronic temporal lobe epilepsy10.1016/j.biomaterials.2016.04.021 ↗
18. PEGylated nanoparticles bind to and alter amyloid-beta peptide conformation: toward engineering of functional nanomedicines for Alzheimer's disease10.1021/nn300489k ↗
19. Endogenous polysialic acid based micelles for calmodulin antagonist delivery against vascular dementia10.1021/acsami.6b13052 ↗
20. Ceria nanoparticles that can protect against ischemic stroke10.1002/anie.201203780 ↗
21. Electroresponsive nanoparticles improve antiseizure effect of phenytoin in generalized tonic-clonic seizures10.1007/s13311-016-0431-9 ↗
22. Functionalized nanocarrier combined seizure-specific vector with P-glycoprotein modulation property for antiepileptic drug delivery10.1016/j.biomaterials.2015.09.041 ↗
23. Cyclic RGD-linked polymeric micelles for targeted delivery of platinum anticancer drugs to glioblastoma through the blood-brain tumor barrier10.1021/nn402662d ↗
24. Nose-to-brain drug delivery by HS15 micelles for brain targeting of insoluble drug
25. Dendrimer advances for the central nervous system delivery of therapeutics10.1021/cn400182z ↗
26. Glioma targeting and blood-brain barrier penetration by dual-targeting doxorubincin liposomes10.1016/j.biomaterials.2013.03.097 ↗
27. Characteristics of sequential targeting of brain glioma for transferrin-modified cisplatin liposome10.1016/j.ijpharm.2013.01.025 ↗
28. STING agonist delivery by lipid calcium phosphate nanoparticles enhances immune activation for neuroblastoma
29. Heterostructures made of upconversion nanoparticles and metal-organic frameworks for biomedical applications
30. Superparamagnetic iron oxide nanoparticles as additives for microwave-based sludge prehydrolysis: a perspective10.1021/acs.est.3c00673 ↗
31. Strategies to improve drug delivery across the blood-brain barrier for glioblastoma10.1007/s11910-024-01338-x ↗
32. Cell-penetrating peptides: promising therapeutics and drug-delivery systems for neurodegenerative diseases10.1021/acs.molpharmaceut.3c01167 ↗
33. Abundance of P-glycoprotein and breast cancer resistance protein measured by targeted proteomics in human epileptogenic brain tissue10.1021/acs.molpharmaceut.1c00083 ↗
34. Strategies for delivering therapeutics across the blood-brain barrier10.1038/s41573-021-00139-y ↗
35. Smart nanotherapeutic targeting of tumor vasculature10.1021/acs.accounts.9b00283 ↗
36. Stimuli-responsive drug release from smart polymers10.3390/jfb10030034 ↗
37. Stimuli-responsive cyclodextrin-based supramolecular assemblies as drug carriers10.1039/D1TB02683F ↗
38. Advanced nanocarbons for enhanced performance and durability of platinum catalysts in proton exchange membrane fuel cells10.1002/smll.202006805 ↗
39. The blood-brain barrier: structure, regulation, and drug delivery10.1038/s41392-023-01481-w ↗
40. Dual and multi-targeted nanoparticles for site-specific brain drug delivery10.1016/j.jconrel.2019.11.037 ↗
41. Management of epileptic disorders using nanotechnology-based strategies for nose-to-brain drug delivery10.1080/17425247.2021.1823965 ↗
42. Nanotechnological advances in the treatment of epilepsy10.2174/1871527321666211221162104 ↗
43. Pathological targets for treating temporal lobe epilepsy: discoveries from microscale to macroscale
44. Familial adult myoclonus epilepsy: neuroimaging and neuropathological findings
45. Biallelic structural variations within FGF12 detected by long-read sequencing in epilepsy10.26508/lsa.202302025 ↗
46. Bursting of excitatory cells is linked to interictal epileptic discharge generation in humans10.1038/s41598-022-10319-4 ↗
47. Neuron-glia interactions in the pathophysiology of epilepsy10.1038/s41583-019-0126-4 ↗
48. Brain concentrations of glutamate and GABA in human epilepsy: a review10.1016/j.seizure.2021.06.028 ↗
49. Ketogenic diet-produced β-hydroxybutyric acid accumulates brain GABA and increases GABA/glutamate ratio to inhibit epilepsy10.1038/s41421-023-00636-x ↗
50. The pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities10.1016/j.neubiorev.2018.02.001 ↗
51. Block of glutamate-glutamine cycle between astrocytes and neurons inhibits epileptiform activity in hippocampus10.1152/jn.00665.2001 ↗
52. Extracellular metabolites in the cortex and hippocampus of epileptic patients10.1002/ana.20380 ↗
53. Elevated basal glutamate and unchanged glutamine and GABA in refractory epilepsy: microdialysis study of 79 patients at the yale epilepsy surgery program10.1002/ana.24673 ↗
54. Milestone Review: metabolic dynamics of glutamate and GABA mediated neurotransmission - the essential roles of astrocytes10.1111/jnc.15811 ↗
55. Glutamatergic mechanisms associated with seizures and epilepsy10.1101/cshperspect.a022863 ↗
56. Role of glutamate excitotoxicity and glutamate transporter EAAT2 in epilepsy: opportunities for novel therapeutics development10.1016/j.bcp.2021.114786 ↗
57. Dynamic transition of neuronal firing induced by abnormal astrocytic glutamate oscillation10.1038/srep32343 ↗
58. Crucial role of astrocytes in temporal lobe epilepsy10.1016/j.neuroscience.2014.12.047 ↗
59. Modulation of intercellular calcium signaling in astrocytes by extracellular calcium and magnesium10.1002/glia.10257 ↗
60. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments10.1038/sj.mp.4001021 ↗
61. Reorganization of the septohippocampal cholinergic fiber system in experimental epilepsy10.1002/cne.24235 ↗
62. Nicotinic acetylcholine receptors and epilepsy10.1016/j.phrs.2023.106698 ↗
63. Immunoreactivity of muscarinic acetylcholine M2 and serotonin 5-HT2B receptors, norepinephrine transporter and Kir channels in a model of epilepsy
64. Dopamine abnormalities in the neocortex of patients with temporal lobe epilepsy10.1016/j.nbd.2011.09.006 ↗
65. Central histaminergic signalling, neural excitability and epilepsy10.1111/bph.15692 ↗
66. Epilepsy, antiepileptic drugs, and aggression: an evidence-based review10.1124/pr.115.012021 ↗
67. Advances in sudden unexpected death in epilepsy10.1111/ane.13715 ↗
68. Serotonergic therapy in epilepsy10.1097/WCO.0000000000000901 ↗
69. Managing brain extracellular K(+) during neuronal activity: the physiological role of the Na(+)/K(+)-ATPase subunit isoforms10.3389/fphys.2016.00141 ↗
70. Contributions of the Na⁺/K⁺-ATPase, NKCC1, and Kir4.1 to hippocampal K⁺ clearance and volume responses10.1002/glia.22629 ↗
71. A fluorescent sensor with high selectivity and sensitivity for potassium in water10.1021/ja0284761 ↗
72. A new highly selective fluorescent K+ sensor10.1021/ja207345s ↗
73. Efficacy and safety of XEN1101, a novel potassium channel opener, in adults with focal epilepsy10.1001/jamaneurol.2023.3542 ↗
74. Astrocytic modulation of neuronal excitability through K+ spatial buffering10.1016/j.neubiorev.2017.03.002 ↗
75. Ion channels as drug targets in central nervous system disorders10.2174/0929867311320100005 ↗
76. NMDA receptor activity downregulates KCC2 resulting in depolarizing GABAA receptor-mediated currents10.1038/nn.2806 ↗
77. Intracellular Ca(2+) release and synaptic plasticity: a tale of many stores10.1177/1073858418785334 ↗
78. Astrocytes modulate neural network activity by Ca2+-dependent uptake of extracellular K+10.1126/scisignal.2002334 ↗
79. The impact of serum magnesium and calcium on the risk of epilepsy: a mendelian randomization study10.1111/cns.14248 ↗
80. Specific imbalance of excitatory/inhibitory signaling establishes seizure onset pattern in temporal lobe epilepsy10.1152/jn.01128.2015 ↗
81. Activation of specific neuronal networks leads to different seizure onset types10.1002/ana.24570 ↗
82. Nonsynaptic modulation of neuronal activity in the brain: electric currents and extracellular ions10.1152/physrev.1995.75.4.689 ↗
83. High-frequency oscillations (HFOs) in clinical epilepsy10.1016/j.pneurobio.2012.03.001 ↗
84. High-frequency oscillations: the state of clinical research10.1111/epi.13829 ↗
85. Automatic vs. manual detection of high frequency oscillations in intracranial recordings from the human temporal lobe10.3389/fneur.2020.563577 ↗
86. Paroxysmal movement disorders and epilepsy: links across the channel10.1212/WNL.55.2.169 ↗
87. On the origin of interictal activity in human temporal lobe epilepsy in vitro10.1126/science.1076510 ↗
88. The role of inflammation in epilepsy10.1038/nrneurol.2010.178 ↗
89. Neuroinflammation and proinflammatory cytokines in epileptogenesis10.1007/s12035-022-02725-6 ↗
90. Brain inflammation in epilepsy: experimental and clinical evidence10.1111/j.1528-1167.2005.00298.x ↗
91. Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures10.1038/nm.2127 ↗
92. Role of transforming growth factor beta in human disease10.1056/NEJM200005043421807 ↗
93. Contribution of nitric oxide, superoxide anion, and peroxynitrite to activation of mitochondrial apoptotic signaling in hippocampal CA3 subfield following experimental temporal lobe status epilepticus10.1111/j.1528-1167.2008.01778.x ↗
94. The development of a novel AND logic based fluorescence probe for the detection of peroxynitrite and GSH10.1039/C8SC00733K ↗
95. Recent progress in the development of fluorescent, luminescent and colorimetric probes for detection of reactive oxygen and nitrogen species10.1039/C6CS00192K ↗
96. Reactive oxygen/nitrogen species and their functional correlations in neurodegenerative diseases10.1007/s00702-011-0758-7 ↗
97. Unraveling mitochondria-targeting reactive oxygen species modulation and their implementations in cancer therapy by nanomaterials
98. Mitochondria, oxidative stress and neurodegeneration10.1016/j.jns.2012.05.030 ↗
99. Diabetes mellitus, mitochondrial dysfunction and Ca2+-dependent permeability transition pore10.3390/ijms21186559 ↗
100. Oxidative stress, mitochondrial dysfunction, and epilepsy10.1080/1071576021000016391 ↗